IncobotulinumtoxinA (Xeomin): background, mechanism of action, and manufacturing.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 23515195.
- Also identified by DOI 10.1177/1090820X12474633.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
IncobotulinumtoxinA is the third botulinum neurotoxin type A (BoNTA) to be approved for aesthetic use in the United States. This article introduces the new product with an overview of clinical applications and a discussion of the neurotoxin's molecular structure. The role and clinical relevance of complexing proteins in BoNTA products are discussed. Finally, incobotulinumtoxinA's mechanism of action is described.
Medical subject headings
- Botulinum Toxins, Type A
- Face
- Neurotransmitter Agents
- Rejuvenation